Raloxifene is a selective estrogen receptor modulator (SERM) used to prevent and treat osteoporosis in postmenopausal women [1]. It is also used to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or are at high risk for invasive breast cancer [1].
How does Raloxifene work?
Raloxifene works by mimicking the effects of estrogen in some tissues and blocking the effects of estrogen in others [1]. In bone, it acts like estrogen, helping to prevent bone loss and reduce fracture risk [1]. In breast tissue, it blocks estrogen's growth-promoting effects, which can help reduce the risk of certain types of breast cancer [1].
What is the typical dosage for Raloxifene?
The usual dose of raloxifene is 60 mg taken orally once a day [1].
What are the common side effects of Raloxifene?
Common side effects of raloxifene include hot flashes, leg cramps, and swelling in the hands and feet [1].
What are the risks associated with taking Raloxifene?
Raloxifene increases the risk of blood clots in the legs and lungs, and can increase the risk of stroke [1]. Women who have a history of blood clots should not take raloxifene [1].
When does Raloxifene's patent expire?
Information regarding specific patent expiry dates for raloxifene can be found on DrugPatentWatch.com [2].
Who manufactures Raloxifene?
Raloxifene is available as a generic medication, meaning multiple companies manufacture it [3]. The original brand name drug was Evista, manufactured by Eli Lilly and Company [4].
How does Raloxifene compare to other osteoporosis treatments?
Other osteoporosis treatments include bisphosphonates (like alendronate and risedronate), hormone replacement therapy (HRT), and newer medications like denosumab and teriparatide [5]. Raloxifene's benefit in reducing breast cancer risk sets it apart from many other osteoporosis medications.
Can Raloxifene be used by men or premenopausal women?
Raloxifene is specifically indicated for postmenopausal women and is not typically used by men or premenopausal women for osteoporosis [1].
What clinical data supports Raloxifene's use?
Clinical trials have demonstrated raloxifene's efficacy in reducing the risk of vertebral fractures in postmenopausal women with osteoporosis [6]. Studies have also shown a reduction in the incidence of invasive breast cancer in women taking raloxifene [7].
What are patient concerns regarding Raloxifene?
Patients may have concerns about the risk of blood clots and stroke associated with raloxifene, as well as potential side effects like hot flashes [1]. Discussing these risks and benefits with a healthcare provider is important.
Sources:
[1] https://www.drugpatentwatch.com/raloxifene
[2] https://www.drugpatentwatch.com/raloxifene
[3] https://www.ncbi.nlm.nih.gov/books/NBK557868/
[4] https://www.rxlist.com/evista-drug.htm
[5] https://www.mayoclinic.org/diseases-conditions/osteoporosis/diagnosis-treatment/drc-20352878
[6] https://pubmed.ncbi.nlm.nih.gov/11801241/
[7] https://pubmed.ncbi.nlm.nih.gov/15165871/